References
- Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213.
- Whitesell L, Shifrin SD, Schwab G, Neckers LM. Benzoquinoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 1992; 52: 1721.
- Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad Sci USA 1994; 91: 8324.
- Grenert JP, Sullivan WP, Fadden P et al. J. Biol Chem. 1997; 272: 23843.
- Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an HSP 90-gel-danamycin complex targeting of a protein chaperone by and antitumor agent. Cell 1997; 89: 239.
- Miller P, DiOrio C, Moyer M et al. Depletion of erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 1994; 54 : 2724.
- Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004; 15: 377.
- Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42: 273.
- Sausville EA, Tomaszewski JE, Ivy P. Clinical develop-ment of 17-allylamino-17-demethoxygeldanamycin. Current Cancer Drug Targets 2003; 3: 377.
- smith v, Sausville EA, Camalier RF, Fiebig HH, Burger AM. 17-DMA-geldanamycin is a novel water soluble Hsp90 inhibitor with potent in vitro and in vivo anticancer activity. Proc. Am. Assoc. Cancer Res 2003; 44 (2nd ed.): 153, #786
- Hollingshead M, Alley M, Burger AM et al. In vivo anti-tumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble gel-danamycin derivative. Cancer Chemother Pharmacol. In press.
- Glaze ER, Lambert AL, Page J et al. Toxicity studies with 17-(dimethylaminoethylamino)-17-demethoxygel-danamycin (17-DMAG; NSC-707545) in rats and dogs. Clin Cancer Res 2003; 9: 6215s.